United States · FDA National Drug Code directory
atoltivimab, maftivimab, and odesivimab
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 61434-052_3c2facc1-3261-b438-e063-6294a90ad2a6
- Product NDC
- 61434-052
- Form
- INJECTION, SOLUTION
- Composition / generic term
- atoltivimab, maftivimab, and odesivimab
- Labeler
- Catalent Indiana, LLC
- Marketing category
- DRUG FOR FURTHER PROCESSING
- Marketing start / end (source format)
- 20201014
- Source listing expiry
- 20261231
Source-listed ingredients
- ATOLTIVIMAB-EBGN — 483.3 mg/14.5mL
- MAFTIVIMAB-EBGN — 483.3 mg/14.5mL
- ODESIVIMAB-EBGN — 483.3 mg/14.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 189 VIAL in 1 CASE (61434-052-00) / 14.5 mL in 1 VIAL · 61434-052-00
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →